MTNB — Matinas BioPharma Holdings, Inc.

NYSE · Health Care · Pharmaceuticals · CIK 1582554 ·
Last close
$0.73
Market Cap
$4.66M
52W High
$0.79
52W Low
$0.48
ADV30
258,954
Next earnings
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -1,936,000 -1,921,000 5,874,000 2,398,000 2,852,000
Dec 2025 0 -1,600,000 -1,912,000 7,208,000 3,999,000 2,378,000
Sep 2025 0 -1,577,000 -1,532,000 9,695,000 5,435,000 3,235,000
Jun 2025 0 -1,837,000 -5,245,000 11,424,000 6,525,000 3,749,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-7,011,000
Investing CF
$335,000
Financing CF
$3,391,000
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.61
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-210,787,000
Inventory
Receivables
ST Investments
$0
EBIT TTM
$-6,960,000
Pretax Income TTM
$-10,345,000
Interest Exp TTM
Analysts

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -6,960,000 -10,345,000 7,208,000 2,378,000 -7,011,000
Dec 2024 0 -20,162,000 -24,251,000 12,641,000 5,051,000 -15,885,000
Dec 2023 1,096,000 -23,766,000 -22,942,000 25,104,000 5,858,000 -15,278,000
Dec 2022 3,188,000 -24,590,000 -20,997,000 44,819,000 8,182,000 -19,156,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-3.00

Peers — same industry

TickerNameMarket CapLastDaily %
PMHS Polomar Health Services, Inc. $4.56M $0.15
ADIL ADIAL PHARMACEUTICALS, INC. $4.80M $2.24
GELS Gelteq Ltd $4.52M $0.42
ENSC Ensysce Biosciences, Inc. $4.52M $0.31
CTTH CTT PHARMACEUTICAL HOLDINGS, INC. $4.85M $0.08

News headlines (Yahoo Finance, 1h cache)

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
2026-04-03 21:00 · Yahoo
Matinas BioPharma Holdings, Inc. (MTNB) Restructures Amid Challenges, Focuses on Oral Antifungal MAT2203
2025-09-23 23:22 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.